Eli Lilly and Co (NYSE:LLY) released topline results from the QWINT-1 and QWINT-3 phase 3 trials evaluating once weekly ...

The Federal Trade Commission (FTC) has filed a legal complaint accusing the 3 largest pharmacy benefit managers (PBMs) in the ...

If you've recently received a diagnosis of type 2 diabetes, understanding your treatment options is an important first step.

The phase 3 SURPASS-4 trial published in 2021 established that tirzepatide lowers blood sugar and supports weight loss better ...

The latest clinical trial results from Eli Lilly show the drug manufacturer's once-weekly insulin injection is just as ...

Semglee has been approved for over a year as a regular biosimilar to Lantus (insulin glargine), meaning that it could be used in place of Sanofi's drug, but only if specifically prescribed for a ...

A pair of late-stage trials found that Eli Lilly’s experimental once-weekly insulin can lower blood sugar as effectively as ...

QWINT-1 evaluated the efficacy and safety of once weekly efsitora compared to once daily insulin glargine for 52 weeks. The trial randomized adults with type 2 diabetes who are insulin naïve to ...

New data show Lilly’s longer-lasting insulin matched daily shots in controlling blood sugar, adding to positive findings the company disclosed in May.

Abbott launched an over-the-counter continuous glucose monitoring system, Lingo, for adults not on insulin -- the second such ...